OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Gepants — a long way to cure: a narrative review
Claudia Altamura, Nicoletta Brunelli, Marilena Marcosano, et al.
Neurological Sciences (2022) Vol. 43, Iss. 9, pp. 5697-5708
Open Access | Times Cited: 31
Claudia Altamura, Nicoletta Brunelli, Marilena Marcosano, et al.
Neurological Sciences (2022) Vol. 43, Iss. 9, pp. 5697-5708
Open Access | Times Cited: 31
Showing 1-25 of 31 citing articles:
Migraine Comorbidities
Dan Iulian Cuciureanu, Cătălina Elena Bistriceanu, Georgiana-Anca Vulpoi, et al.
Life (2024) Vol. 14, Iss. 1, pp. 74-74
Open Access | Times Cited: 10
Dan Iulian Cuciureanu, Cătălina Elena Bistriceanu, Georgiana-Anca Vulpoi, et al.
Life (2024) Vol. 14, Iss. 1, pp. 74-74
Open Access | Times Cited: 10
Real-world effectiveness of Anti-CGRP monoclonal antibodies compared to OnabotulinumtoxinA (RAMO) in chronic migraine: a retrospective, observational, multicenter, cohort study
Licia Grazzi, Riccardo Giossi, Danilo Antonio Montisano, et al.
The Journal of Headache and Pain (2024) Vol. 25, Iss. 1
Open Access | Times Cited: 10
Licia Grazzi, Riccardo Giossi, Danilo Antonio Montisano, et al.
The Journal of Headache and Pain (2024) Vol. 25, Iss. 1
Open Access | Times Cited: 10
Acute Treatment of Migraine: Expert Consensus Statements from the United Arab Emirates (UAE)
Taoufik Alsaadi, Deeb Maxwell Kayed, Abubaker Almadani, et al.
Neurology and Therapy (2024) Vol. 13, Iss. 2, pp. 257-281
Open Access | Times Cited: 7
Taoufik Alsaadi, Deeb Maxwell Kayed, Abubaker Almadani, et al.
Neurology and Therapy (2024) Vol. 13, Iss. 2, pp. 257-281
Open Access | Times Cited: 7
Effectiveness and tolerability of rimegepant in the acute treatment of migraine: a real-world, prospective, multicentric study (GAINER study)
Luigi Francesco Iannone, Gloria Vaghi, Gabriele Sebastianelli, et al.
The Journal of Headache and Pain (2025) Vol. 26, Iss. 1
Open Access
Luigi Francesco Iannone, Gloria Vaghi, Gabriele Sebastianelli, et al.
The Journal of Headache and Pain (2025) Vol. 26, Iss. 1
Open Access
The efficacy and safety of zavegepant nasal inhalation versus oral calcitonin-gene related peptide receptor antagonists in the acute treatment of migraine: a systematic review and network meta-analysis of the literature
Zixiang Zhu, Yanbing Tang, Long‐Yuan Li, et al.
The Journal of Headache and Pain (2025) Vol. 26, Iss. 1
Open Access
Zixiang Zhu, Yanbing Tang, Long‐Yuan Li, et al.
The Journal of Headache and Pain (2025) Vol. 26, Iss. 1
Open Access
CGRP: vom Neuropeptid zum therapeutischen Target (Hintergründe und Pathophysiologie)
Katharina Kamm
Nervenheilkunde (2025) Vol. 43, Iss. 04, pp. 222-231
Closed Access
Katharina Kamm
Nervenheilkunde (2025) Vol. 43, Iss. 04, pp. 222-231
Closed Access
Jim H. Hughes, Richard Bertz, Rajinder Bhardwaj, et al.
CPT Pharmacometrics & Systems Pharmacology (2024) Vol. 13, Iss. 6, pp. 1044-1054
Open Access | Times Cited: 4
Calcitonin gene-related peptide-targeted therapy in migraine: current role and future perspectives
Jan Versijpt, Koen Paemeleire, Uwe Reuter, et al.
The Lancet (2025) Vol. 405, Iss. 10483, pp. 1014-1026
Closed Access
Jan Versijpt, Koen Paemeleire, Uwe Reuter, et al.
The Lancet (2025) Vol. 405, Iss. 10483, pp. 1014-1026
Closed Access
Calcitonin Gene-Related peptide receptor antagonist suppresses allergic asthma responses via downregulation of group 2 innate lymphoid cells in mice
Erina Ike, Tasuku Kawano, Kento Takahashi, et al.
International Immunopharmacology (2023) Vol. 122, pp. 110608-110608
Closed Access | Times Cited: 10
Erina Ike, Tasuku Kawano, Kento Takahashi, et al.
International Immunopharmacology (2023) Vol. 122, pp. 110608-110608
Closed Access | Times Cited: 10
A Brief Review of Gepants
Diana Li, Jessica Abreu, Stewart J. Tepper
Current Pain and Headache Reports (2023) Vol. 27, Iss. 9, pp. 479-488
Closed Access | Times Cited: 10
Diana Li, Jessica Abreu, Stewart J. Tepper
Current Pain and Headache Reports (2023) Vol. 27, Iss. 9, pp. 479-488
Closed Access | Times Cited: 10
Towards precision medicine in migraine: Recent therapeutic advances and potential biomarkers to understand heterogeneity and treatment response
Gabriella Juhász, Kinga Gecse, Dániel Baksa
Pharmacology & Therapeutics (2023) Vol. 250, pp. 108523-108523
Open Access | Times Cited: 10
Gabriella Juhász, Kinga Gecse, Dániel Baksa
Pharmacology & Therapeutics (2023) Vol. 250, pp. 108523-108523
Open Access | Times Cited: 10
Calcitonin Gene-Related Peptide Systemic Effects: Embracing the Complexity of Its Biological Roles—A Narrative Review
Adriano Bonura, Nicoletta Brunelli, Marilena Marcosano, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 18, pp. 13979-13979
Open Access | Times Cited: 9
Adriano Bonura, Nicoletta Brunelli, Marilena Marcosano, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 18, pp. 13979-13979
Open Access | Times Cited: 9
Rimegepant and atogepant: novel drugs providing innovative opportunities in the management of migraine
William Wells-Gatnik, Lanfranco Pellesi, Paolo Martelletti
Expert Review of Neurotherapeutics (2024), pp. 1-11
Closed Access | Times Cited: 3
William Wells-Gatnik, Lanfranco Pellesi, Paolo Martelletti
Expert Review of Neurotherapeutics (2024), pp. 1-11
Closed Access | Times Cited: 3
Combining treatments for migraine prophylaxis: the state-of-the-art
Lanfranco Pellesi, David García‐Azorín, Eloísa Rubio‐Beltrán, et al.
The Journal of Headache and Pain (2024) Vol. 25, Iss. 1
Open Access | Times Cited: 3
Lanfranco Pellesi, David García‐Azorín, Eloísa Rubio‐Beltrán, et al.
The Journal of Headache and Pain (2024) Vol. 25, Iss. 1
Open Access | Times Cited: 3
Voltage-gated Calcium Channels as Potential Therapeutic Targets in Migraine
Juliana Geremias Chichorro, Eder Gambeta, Darciane Favero Baggio, et al.
Journal of Pain (2024) Vol. 25, Iss. 8, pp. 104514-104514
Closed Access | Times Cited: 2
Juliana Geremias Chichorro, Eder Gambeta, Darciane Favero Baggio, et al.
Journal of Pain (2024) Vol. 25, Iss. 8, pp. 104514-104514
Closed Access | Times Cited: 2
Revolutionizing migraine management: advances and challenges in CGRP-targeted therapies and their clinical implications
Aynur Özge, Betül Baykan, Şebnem Bıçakcı, et al.
Frontiers in Neurology (2024) Vol. 15
Open Access | Times Cited: 2
Aynur Özge, Betül Baykan, Şebnem Bıçakcı, et al.
Frontiers in Neurology (2024) Vol. 15
Open Access | Times Cited: 2
Reduced hepatic impairment study to evaluate pharmacokinetics and safety of zavegepant and to inform dosing recommendation for hepatic impairment
Rajinder Bhardwaj, Mary Donohue, Jennifer Madonia, et al.
Clinical and Translational Science (2024) Vol. 17, Iss. 7
Open Access | Times Cited: 2
Rajinder Bhardwaj, Mary Donohue, Jennifer Madonia, et al.
Clinical and Translational Science (2024) Vol. 17, Iss. 7
Open Access | Times Cited: 2
Focus On Zavegepant: The First Intranasal Third-Generation Gepant
Damiana Scuteri, Assunta Tarsitano, Paolo Tonin, et al.
Pain Management (2022) Vol. 12, Iss. 8, pp. 879-885
Closed Access | Times Cited: 10
Damiana Scuteri, Assunta Tarsitano, Paolo Tonin, et al.
Pain Management (2022) Vol. 12, Iss. 8, pp. 879-885
Closed Access | Times Cited: 10
Eptinezumab for the Prevention of Migraine: Clinical Utility, Patient Preferences and Selection – A Narrative Review
Claudia Altamura, Nicoletta Brunelli, Marilena Marcosano, et al.
Therapeutics and Clinical Risk Management (2023) Vol. Volume 19, pp. 959-971
Open Access | Times Cited: 4
Claudia Altamura, Nicoletta Brunelli, Marilena Marcosano, et al.
Therapeutics and Clinical Risk Management (2023) Vol. Volume 19, pp. 959-971
Open Access | Times Cited: 4
Clinical Management of Migraine
Maria Albanese
Journal of Clinical Medicine (2022) Vol. 11, Iss. 17, pp. 5225-5225
Open Access | Times Cited: 3
Maria Albanese
Journal of Clinical Medicine (2022) Vol. 11, Iss. 17, pp. 5225-5225
Open Access | Times Cited: 3
Update on gepants for the treatment of chronic migraine
Yu Aoh, Tsung-Wei Hou, Cheng‐Chia Yang, et al.
Journal of the Chinese Medical Association (2024) Vol. 87, Iss. 4, pp. 350-356
Open Access
Yu Aoh, Tsung-Wei Hou, Cheng‐Chia Yang, et al.
Journal of the Chinese Medical Association (2024) Vol. 87, Iss. 4, pp. 350-356
Open Access
CGRP: vom Neuropeptid zum therapeutischen Target (Hintergründe und Pathophysiologie)
Katharina Kamm
Fortschritte der Neurologie · Psychiatrie (2024) Vol. 92, Iss. 07/08, pp. 267-276
Closed Access
Katharina Kamm
Fortschritte der Neurologie · Psychiatrie (2024) Vol. 92, Iss. 07/08, pp. 267-276
Closed Access
Adverse event analysis and signal detection of calcitonin gene-related peptide inhibitors using the FDA Adverse Event Reporting System database
Nai Lee, Jihoon Ok, Jong‐Hyun Lee, et al.
Research Square (Research Square) (2024)
Closed Access
Nai Lee, Jihoon Ok, Jong‐Hyun Lee, et al.
Research Square (Research Square) (2024)
Closed Access
Role of calcitonin gene-related peptide (CGRP) receptor antagonist in acute and preventive treatment of migraine.
Michał Dacka, Mateusz Sobczyk, Paulina Dąbrowska, et al.
Prospects in Pharmaceutical Sciences (2024) Vol. 22, Iss. 3, pp. 21-26
Open Access
Michał Dacka, Mateusz Sobczyk, Paulina Dąbrowska, et al.
Prospects in Pharmaceutical Sciences (2024) Vol. 22, Iss. 3, pp. 21-26
Open Access
Rimegepant - a breakthrough drug for migraine treatment - literature review
Katarzyna Kuleta, Julia Głoskowska, Agata Frańczuk, et al.
Quality in Sport (2024) Vol. 19, pp. 54030-54030
Open Access
Katarzyna Kuleta, Julia Głoskowska, Agata Frańczuk, et al.
Quality in Sport (2024) Vol. 19, pp. 54030-54030
Open Access
